SG/CALL/ELI LILLY & CO/450/0.1/21.06.24 | Market Closed - Deutsche Boerse AG 17:49:51 13/06/2024 BST | ||
| 39.48 EUR | +2.73% |
|
| Current month | +17.33% | ||
| 1 month | +37.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 13/06/24 | 39.48 | +2.73% |
| 12/06/24 | 38.43 | -0.72% |
| 11/06/24 | 38.71 | -0.23% |
| 10/06/24 | 38.8 | +4.55% |
| 07/06/24 | 37.11 | +4.62% |
Delayed Quote Deutsche Boerse AG
Last update June 13, 2024 at 05:49 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SQ4FHC |
| ISIN | DE000SQ4FHC1 |
| Date issued | 16/11/2022 |
| Strike | 450 $ |
| Maturity | 21/06/2024 (5 Days) |
| Parity | 10 : 1 |
| Emission price | 3.75 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 41.06 € |
|---|---|
| Lowest since issue | 1.05 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
878.4
USD
Average target price
855.4
USD
Spread / Average Target
-2.63%
- Stock Market
- Warrants
- Warrant